Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Avantor, Inc. ("Avantor, Inc." or the "Company") (NYSE: AVTR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avantor, Inc. investors who were adversely affected by alleged securities fraud between March 5, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/avantor-inc-lawsuit-subm ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Allegations and Financial Performance - The lawsuit claims that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and that the company was experiencing strength in Europe and South Korea. However, it is alleged that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and jeopardizing the business model [5]. - On September 9, 2025, Synopsys reported Q3 2025 financial results, revealing that its Design IP segment generated revenue of $425.9 million, a 7.7% year-over-year decline, and net income of $242.5 million, a 43% year-over-year decline. The company indicated that increased customization demands from customers were leading to longer timelines and more resource requirements, prompting discussions about changing its business model [6]. Stock Market Reaction - Following the release of the disappointing financial results, Synopsys's stock price fell by $217.59 per share, nearly 36%, from $604.37 on September 9, 2025, to $387.78 on September 10, 2025 [6].

Core Viewpoint - A federal securities class action has been filed against Coupang, Inc. alleging securities fraud and other unlawful business practices during the Class Period from August 6, 2025, to December 16, 2025 [1][6]. Group 1: Lawsuit Details - The lawsuit centers on a major data breach affecting approximately 33.7 million customer accounts, involving unauthorized access to personal information [6]. - Investors who purchased Coupang securities during the Class Period may seek appointment as Lead Plaintiff by February 17, 2026 [1][6]. - The complaint alleges that material facts regarding data security, internal controls, and compliance were misstated or omitted, leading to investor losses when the truth emerged [6]. Group 2: Impact on Stock Price - Following media reports and regulatory developments concerning the data breach, including a Reuters article on November 30, 2025, Coupang's stock price declined on several dates [6]. - The resignation of the CEO and an emergency government meeting in South Korea were significant events that contributed to the decline in stock price [6].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Skye securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding Skye's business, operations, and prospects [3]. - Specific allegations include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [8]. Group 2: Investor Participation - Investors who suffered losses in Skye have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

Core Viewpoint - A class action lawsuit has been filed against Firefly Aerospace Inc. and certain officers for alleged violations of federal securities laws related to its IPO and subsequent securities transactions [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Firefly securities during the Class Period from August 7, 2025, to September 29, 2025 [2]. - The Complaint alleges that the Offering Documents were negligently prepared, containing untrue statements of material fact and omitting necessary information, thus misleading investors [3]. - Specific allegations include overstated demand for Spacecraft Solutions, overstated operational readiness of the Alpha rocket program, and the potential material negative impact on the company once these facts were revealed [3]. Group 2: Investor Information - Investors wishing to join the lawsuit must act by January 12, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if successful in the lawsuit [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6]. - The firm emphasizes its commitment to restoring investor capital and ensuring corporate accountability to maintain market integrity [6].

Core Viewpoint - A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) for allegedly defrauding investors by executing manipulative trades that artificially deflated the price of Quantum Biopharma Ltd. (Quantum) securities [1][3]. Summary by Sections Lawsuit Details - The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of all individuals and entities that sold Quantum securities between January 6, 2021, and October 15, 2025, inclusive [2]. - The Complaint alleges that Defendants engaged in thousands of spoofed sell orders to create a false appearance of declining stock prices, deceiving investors into selling shares at artificially depressed prices [3]. Allegations Against Defendants - Defendants are accused of making materially false and misleading statements and failing to disclose manipulative trading practices [3]. - The manipulative orders were designed to induce investors to sell their shares at lower prices, after which the Defendants purchased shares at these artificially deflated levels to profit from the scheme [3]. Next Steps for Investors - Investors who suffered losses in Quantum have until February 23, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 15, 2022, to September 24, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Freeport securities during the specified Class Period [2]. - Allegations include that Freeport failed to ensure safety at the Grasberg Block Cave mine in Indonesia, leading to heightened risks for workers [3]. - The complaint claims that the defendants made false or misleading statements regarding Freeport's business operations and prospects, which were materially false and misleading [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by January 12, 2026, although participation in any recovery does not require this role [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the Class Period from February 21, 2025, to August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Telix securities during the specified Class Period [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit can review the complaint and are encouraged to contact the law firm for further information [4]. - A deadline of January 9, 2026, has been set for investors to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].